Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LYKA LABS Gains 6%; BSE HEALTHCARE Index Down 0.3%
Thu, 29 Aug 13:54

LYKA LABS Gains 6%; BSE HEALTHCARE Index Down 0.3%Image source: StarLineArts/www.istockphoto.com

LYKA LABS share price has zoomed 6% and is presently trading at Rs 151.1.

Meanwhile, the BSE HEALTHCARE index is at 42,610.9 (down 0.3%).

Among the top gainers in the BSE HEALTHCARE index today are AJANTA PHARMA (up 2.3%) and ERIS LIFESCIENCES (up 1.8%).

Natco Pharma (down 2.7%) and CAPLIN POINT (down 2.2%) are among the top losers today.

Over the last one year, LYKA LABS has moved up from Rs 117.3 to Rs 151.1, registering a gain of Rs 33.9 (up 28.9%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,859.6 to 42,610.9, registering a gain of 52.9% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 134.8%), Glenmark Pharma (up 120.9%) and SUVEN PHARMACEUTICALS (up 106.4%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 82,201.6 (up 0.5%).

The top gainers among the BSE Sensex today are Bajaj Finance (up 2.8%) and Bajaj Finserv (up 2.5%). The most traded stocks in the BSE Sensex are Tata Steel and HDFC Bank.

In the meantime, NSE Nifty is at 25,140.1 (up 0.4%). Bajaj Finserv and Bajaj Finance are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,996.6 to 82,201.6, registering a gain of 17,205.0 points (up 26.5%).

LYKA LABS Financial Update...

LYKA LABS net profit grew 166.8% YoY to Rs 13 million for the quarter ended June 2024, compared to a loss of Rs 19 million a year ago. Net sales rose 31.6% to Rs 301 million during the period as against Rs 229 million in April-June 2023.

For the year ended March 2024, LYKA LABS reported 80.1% increase in net profit to Rs -26 million compared to net loss of Rs 132 million during FY23. Revenue of the company grew 19.5% to Rs 1,112 million during FY24.

The current Price to earnings ratio of LYKA LABS, based on rolling 12 month earnings, stands at 898.9.

Archives


Equitymaster requests your view! Post a comment on "LYKA LABS Gains 6%; BSE HEALTHCARE Index Down 0.3%". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.